prikaz prve stranice dokumenta Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus
  Preuzmi
PDF 1.18 MB
Znanstveni rad - Pregledni rad
Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus
Annals of Hematology, 102 (2023), 4; 715-727. https://doi.org/10.1007/s00277-023-05114-8
Pulanić, Dražen; Bátorová, Angelika; Bodó, Imre; Červinek, Libor; Ionita, Ioana; Lissitchkov, Toshko; Melikyan, Anahit; Podolak-Dawidziak, Maria

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Pulanić, D., Bátorová, A., Bodó, I., Červinek, L., Ionita, I., Lissitchkov, T. ... Podolak Dawidziak, M. (2023). Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. Annals of Hematology, 102. (4), 715-727. doi: 10.1007/s00277-023-05114-8

Pulanić, Dražen, et al. "Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus." Annals of Hematology, vol. 102, br. 4, 2023, str. 715-727. https://doi.org/10.1007/s00277-023-05114-8

Pulanić, Dražen, Angelika Bátorová, Imre Bodó, Libor Červinek, Ioana Ionita, Toshko Lissitchkov, Anahit Melikyan i Maria Podolak Dawidziak. "Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus." Annals of Hematology 102, br. 4 (2023): 715-727. https://doi.org/10.1007/s00277-023-05114-8

Pulanić, D., et al. (2023) 'Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus', Annals of Hematology, 102(4), str. 715-727. doi: 10.1007/s00277-023-05114-8

Pulanić D, Bátorová A, Bodó I, Červinek L, Ionita I, Lissitchkov T, i sur.. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. Annals of Hematology [Internet]. 24.02.2023. [pristupljeno 10.05.2024.];102(4):715-727. doi: 10.1007/s00277-023-05114-8

D. Pulanić, et al., "Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus", Annals of Hematology, vol. 102, br. 4, str. 715-727, Veljača 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:190319. [Citirano: 10.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:190319
Podaci o radu
Naslov (engleski)Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus
AutorDražen Pulanić
AutorAngelika Bátorová
AutorImre Bodó
AutorLibor Červinek
AutorIoana Ionita
AutorToshko Lissitchkov
AutorAnahit Melikyan
AutorMaria Podolak-Dawidziak
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
There are currently three thrombopoietin receptor agonists (TPO-RAs) approved in Europe for treating patients with immune thrombocytopenia (ITP): romiplostim (Nplate®), eltrombopag (Revolade®), and avatrombopag (Doptelet®). However, comparative clinical data between these TPO-RAs are limited. Therefore, the purpose of this study was to perform a literature review and seek expert opinion on the relevance and strength of the evidence concerning the use of TPO-RAs in adults with ITP. A systematic search was conducted in PubMed and Embase within the last 10 years and until June 20, 2022. A total of 478 unique articles were retrieved and reviewed for relevance. The expert consensus panel comprised ITP senior hematologists from eight countries across Central Europe. The modified Delphi method, consisting of two survey rounds, a teleconference and email correspondence, was used to reach consensus. Forty articles met the relevancy criteria and are included as supporting evidence, including five meta-analyses analyzing all three European-licensed TPO-RAs and comprising a total of 31 unique randomized controlled trials (RCTs). Consensus was reached on seven statements for the second-line use of TPO-RAs in the management of adult ITP patients. In addition, the expert panel discussed TPO-RA treatment in chronic ITP patients with mild/moderate COVID-19 and ITP patients in the first-line setting but failed to reach consensus. This work will facilitate informed decision-making for healthcare providers treating adult ITP patients with TPO-RAs. However, further studies are needed on the use of TPO-RAs in the first-line setting and specific patient populations.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaAnnals of Hematology
Brojčani podacivol. 102, br. 4, str. 715-727
p-ISSN0939-5555
e-ISSN1432-0584
DOIhttps://doi.org/10.1007/s00277-023-05114-8
URN:NBNurn:nbn:hr:105:190319
Datum objave publikacije2023-02-24
URL dokumentahttps://link.springer.com/10.1007/s00277-023-05114-8
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-15 09:15:17